.jpg)
Contents
In this issue:
- Clinical Research Roadmap is launched
- SFI/MMI Technology Platform Workshop 3 June 2010
- MMI strengthens national network to support industry-sponsored trials
- DCCR contract finalised
- MMI agrees position paper calling for Ireland's continued participation in EU biobanking and clinical research infrastructures
- Date for the diary - Workshop on Sponsorship and Governance of Clinical Research
- ICRIN invites applications for the next GCP course on Friday 16th July 2010, which will take place in St Vincent's Hospital, Dublin 4
- MMI/ICRIN contributes to ECRIN publications
- MMI Course Visit to Trinity College Dublin's 3D Visualisation Facility
- Predictive Biomarkers in Breast Cancer Discovered by Research Team including MMI Clinician Scientist Fellow
- Funding confirmed for Galway Clinical Research Facility
- News In Brief
- Upcoming Events
Clinical Research Roadmap is launched
.jpg)
A new Clinical Research Roadmap that will improve outcomes for patients, create jobs in health related industries in Ireland and enhance clinical research was launched by Mary Harney TD, Minister for Health and Children on Tuesday 1 June in the Royal College of Physicians of Ireland.
Up to 80 people from the public and private health sectors attended the launch which was held in the Royal College of Physicians of Ireland. The Roadmap was widely welcomed as a significant step towards the further development and enhancement of Ireland’s clinical research infrastructure and an important contribution towards the country’s economic renewal.
The Clinical Research Roadmap highlights the strategic and operational changes needed to improve Ireland’s capacity to undertake high quality, multi-centre clinical research. These changes are needed to develop new medicines, diagnostics, therapeutics and medical devices and to allow Ireland participate in European research initiatives.
The Roadmap looks at how we can create a coordinated, networked clinical research system in Ireland. The Roadmap was developed by the Irish Clinical Research Infrastructure Network (ICRIN)*, which is funded by the Health Research Board and the HSE. The Roadmap brings together the ideas and knowledge of the best minds in clinical research - regulators, funders, researchers, industry associations, hospitals, universities and patient organisations.
Pictured at the launch of the Clinical Research Roadmap (l to r): Professor Larry Egan (Clinical Director of ICRIN), Dr Ruth Barrington (CEO of MMI), Dr Damian O' Connell (Chair of MMI), Mary Harney TD (Minister for Health and Children), John Mc Cormack (Chair of Medical Research Charities Group) and Enda Connolly (CEO of Health Research Board)
In launching the Roadmap, Mary Harney TD, Minister for Health and Children says that the Government is committed to building capacity for clinical research in Ireland and acknowledged the Roadmap as an important contribution in this regard.
Speaking at the launch, Professor Lawrence Egan, Clinical Director of ICRIN and Interim Director of Galway Clinical Research Facility, said, "Our vision is to incorporate clinical research into the everyday care of patients”. Referring to the importance of partnership, he emphasised that "ICRIN’s Clinical Research Roadmap represents an opportunity for funders, researchers, industry and the health service to build together an Irish clinical research system that will achieve this vision".
Dr Damian O’Connell, Chairman of Molecular Medicine Ireland and Vice President of Pfizer Clinical R&D said, "The Government is committed to making Ireland a leading country for the timing, access and relevance of clinical trials. The Clinical Research Roadmap is an important contribution, as to how, in practice, this national objective can be achieved. A great deal of investment in clinical research infrastructure has already been made in Dublin, Galway and Cork. What we need to do now is move quickly to create a sustainable, national system to support clinical research. I would like to thank everyone who had had a role in developing the Roadmap".
Speaking from an industry perspective, Dr O’Connell emphasised the need for Ireland to prioritise and map its clinical research strengths and health needs in order to attract industry sponsored clinical trials. He said, “Building the patient registries and bio collections linked to those priorities, coupled with a much improved capacity to undertake clinical trials, will be of interest to industry and will generate more clinical research and more jobs in Ireland”.
Also speaking at the launch, Enda Connolly, Chief Executive at the Health Research Board, said, “The HRB is driving the growth of clinical research in Ireland. Developing a strong coherence across the Irish health and research systems is central to this. We have supported ICRIN to develop this Roadmap because it will help create the vibrant, co-ordinated clinical research system we need here. When this is in place, Ireland will be in a much better position to absorb new innovations and support high performance in our health system. This will improve people’s health as well as attracting industry investment”.
John McCormack, Chair of the Medical Research Charities Group and CEO of the Irish Cancer Society welcomed the Roadmap and commented that, “There are great opportunities to improve health outcomes for Irish people through clinical research. There is also great potential for patients to avail of the latest treatments for their conditions by taking part in clinical studies. If the recommendations of the Roadmap are implemented, the benefits of clinical research will be made more widely available. The Medical Research Charities Group encourages patients to avail of every opportunity to participate in clinical research studies in our hospitals".
The launch closed with a universal call for the implementation of the Roadmap.
To view the Clinical Research Roadmap please click here.
SFI/MMI Technology Platform Workshop 3 June 2010
SFI in association with MMI organised a Technology Platform Workshop on June 3rd 2010 at the Institute for Molecular Medicine in St James Hospital in order to showcase the breadth of technology platforms in Ireland and to highlight how these technologies are:
- Operating as national and/or all-island facilities
- Contributing to Ireland’s innovation and commercialisation agenda
- Facilitating partnerships with industry
We were delighted to note that this workshop was well attended with representation from many institutions across the country, both north and south. The workshop was opened jointly by Dr Ruth Barrington of MMI and Dr Stephen Simpson of SFI who highlighted the interest of both organisations in developing a better understanding of the contribution of technology platforms. Dr Jan Guerin of MMI launched the Technology Platform Web-Portal developed to promote technologies that support clinical and translational research in Ireland: http://www.molecularmedicineireland.ie/tp_web_portal. The web-portal currently profiles over 60 technology platforms available for biomedical research on the island of Ireland.
Dr Eucharia Meehan of the Higher Education Authority, whose Programme for Research in Third Level Education funded the establishment of many technology platforms throughout Ireland, chaired the first session on how technology platforms operate as national and/or all-island facilities. Mr. Martin Shanagher from the Department of Enterprise, Trade and Innovation, chaired the session focusing on how technology platforms are addressing the innovation and commercialisation agenda. Mr Shanagher led this session by highlighting the Government’s recognition that investment in science and research is central to Ireland’s economic recovery. Dr Brian Kelly of Celtic Catalysts and a member of the Innovation Task Force chaired the session that highlighted how technology platforms facilitate partnerships with industry.
The presentations for all three sessions included researchers from a number of universities in Ireland who clearly demonstrated how technology platforms are actively contributing to Ireland’s research and innovation agenda and forging strong partnerships with industry. These presentations also highlighted the availability of these state-of-the-art technologies, many organised as national facilities, to researchers throughout Ireland.
In addition to the broad range of oral presentations, there were a number of posters (as highlighted in the above image) showcasing the contribution of their technology platforms to these thematic areas.
The keynote speaker was Dr. Christian Boulin, Head of Core Facilities at EMBL, who provided a comprehensive overview of the state-of-art facilities available through EMBL to Irish researchers and who encouraged more Irish researchers to avail of EMBL’s technologies and expertise.
The final session, chaired by Dr Ruth Barrington, provided a lively discussion around the use and sustainability of technology platforms. The panel members for this session were Sean Mulvany (EI), Stephen Simpson (SFI), Enda Connelly (HRB), Christian Boulin (EMBL), John Boland (CRANN) and Bert Rima (QUB) who shared their views openly on this important topic.
To conclude the day, Ruth Barrington thanked the speakers, chairs, panel members, oral and poster presenters for participating in the workshop and for contributing to such a stimulating day. On behalf of all those attending, she thanked Jan Guerin, Siobhan Roche and Michael Ryan for their hard work in planning and organising the workshop. She invited more researchers to display their technology platforms on the MMI Technology Platform Web-portal and said that the proceedings of the workshop would be prepared and circulated with a view to promoting a more strategic approach to sustain the substantial investment in infrastructure and expertise of the past ten years.
MMI in association with SFI are currently drafting the proceedings for the Workshop which will be made available in the coming week at the following link: http://www.molecularmedicineireland.ie/tp_web_portal
Please click here for a copy of the programme of speakers for this workshop.
MMI strengthens national network to support industry-sponsored trials
Speaking recently at the launch of the Clinical Research Roadmap, Dr Damian O' Connell, Chair of Molecular Medicine Ireland announced that the MMI partners would work together to increase the number multi-centre clinical studies in Ireland and in particular, to improve the experience of industry in conducting clinical trials in Ireland. He said that MMI was taking this initiative in the context of the Renewed Programme for Government which commits the government parties to making Ireland ‘a leading country for the timing, access and relevance of clinical trials'.
Dr Damian O’ Connell (Chair, MMI) with Dr Ruth Barrington (CEO, MMI) and Mary Harney TD, Minister for Health and Children
The recently published Report of the Innovation Task Force endorses the need for strong alliances between third level institutions that focus on innovation. It highlights the opportunities for this country to capture innovation from convergent technologies in the pharmaceutical and biotech sectors and from our strengths in research on food and health, and expertise in medical device technologies. It also points out that ‘the development of a clinical trials research system is critical for the future growth and development of this sector in Ireland (both indigenous and MNCs) and to ensure that we leverage investments in research and development - translating from bench to bedside.’
Dr O’Connell, who is also Vice President for Research and Development with Pfizer, referred to an address he had made at the IPPOSI Strategic Forum on Clinical Research in November 2009. ‘I spoke about the changes in the way the pharmaceutical industry funds clinical research and what Ireland has to do to become a core site again for clinical trials.’ A combination of logistical problems and financial pressures has led companies to reduce the number of countries in which they conduct clinical trials as a strategy to increase the speed of study execution and reduce costs while maintaining quality. ‘At an operational level, industry – both global and indigenous - wants a rapid assessment of the feasibility of a study, no undue delays between the decision to conduct the study and the recruitment of the first patients and the target patient population recruited within the agreed timescale’, he commented. Industry wants predictable costs and a high level of regulatory compliance and it wants to be able to navigate the system of clinical research easily.
‘At a strategic level, we need to be able to tell industry what we are good at researching in this country and what matters to us in terms of improving the health of the population’, Dr O’Connell continued. ‘As a small country, we cannot be good at everything so we must prioritise and map our clinical research strengths and our health needs. Building the patient registries and bio collections linked to those priorities, coupled with a much improved capacity to undertake clinical trials, will be of interest to industry and will generate more clinical research and more jobs in Ireland.’
Dr O’Connell asked the question ‘what can MMI and its partners offer industry?' The answer is that MMI can offer the support of the network of clinical research centres that are in place or planned across the country for which the MMI partners are responsible. The CRCs established by RCSI (Beaumont Hospital), UCD (Mater and St Vincent’s), NUI Galway (University College Hospital) and the emerging CRCs TCD (St James’s Hospital) and UCC (Mercy University Hospital) have extensive experience of conducting clinical research, including clinical trials, to a high standard. Each CRC can support academic and industry sponsored studies to standards and timelines that PIs operating independently can find difficult to meet. As a network of CRCs, they can offer support for studies of a scale or of a complexity that have been difficult to undertake in Ireland before now.
Dr O’Connell said that as Chairman of MMI he was pleased to announce that the MMI Board has endorsed the creation of an ICRIN Working Group that, before the end of 2010, will address the following issues:
- Enable a rapid assessment of the feasibility of undertaking studies across the network
- Oversee the adoption of the research readiness programme in participating CRCs and research groups
- Agree and adopt a schedule of research services and predictable charges to industry for the standard research procedures to be carried out in multi-site studies in the network
- Will negotiate with the MMI partners and those associated hospitals that are responsible for Recognised Ethics Committees (RECs), a memorandum of agreement around agreed timelines for the ethical review of industry-sponsored, multi-centre clinical trials to be carried out by the network, for electronic submission of applications to the RECs and for parallel site specific assessment for hospital participation in such studies. The performance of the partners against agreed metrics of performance to be audited by an independent third party and published annually
- Following a trial period of a clinical informatics system in the Dublin Centre for Clinical Research later this year, the ICRIN Network Committee will commit to adopting a common clinical informatics platform across the network
- The ICRIN Working Group will seek resources to develop a web portal with a strong industry facing dimension to promote the research ready network, assist industry navigate the resources available to support their clinical trials and highlight the benefits to industry of undertaking clinical trials through the network in Ireland
- Will address such other issues that arise in consultation with industry to make Ireland a more attractive location for industry sponsored clinical trials.
The ICRIN Working Group is chaired by Professor Larry Egan, Acting Clinical Director of the NUI Galway CRC at University College Hospital Galway. Its members include leading clinical researchers responsible for the CRCs in place or planned in Dublin, Cork and Galway. Dr O’Connell said that the Group would work closely with all stakeholders to facilitate multi-centre studies. ‘This initiative demonstrates the MMI partners’ commitment to implementing key recommendations of the Clinical Research Roadmap and to making Ireland a leading country for the conduct of clinical trials’, Dr O’Connell said.
For further information please contact Marie Mellody, ICRIN Coordinator, marie.mellody@molecularmedicineireland.ie
DCCR contract finalised
In June 2006 a bid by the Dublin Molecular Medicine Centre involving TCD, RCSI and UCD and led by Professor Dermot Kelleher, succeeded in securing approximately €23 million from the Wellcome Trust and the Health Research Board for the Dublin Centre for Clinical Research (DCCR). The aim of the DCCR is to provide the infrastructure – physical space, facilities and trained staff – needed to support collaborative clinical research studies across Dublin. The Wellcome Trust will cover the construction and equipment costs of a new clinical research centre at St. James’ Hospital while the HRB will support the initial running costs of the CRC as well as the costs of the DCCR Clinical Research Network for a period of five years. The DCCR network includes clinical research activites undertaken at the RCSI CRC at Beaumont Hospital, the UCD CRC at the Mater Misericordae University Hospital and St. Vincent’s University Hospital, and the clinical research centre at St. James’s Hospital when completed.
The signing of the tripartite Wellcome Trust Agreement in December 2009 between Trinity College Dublin, St. James’s Hospital Board and the Wellcome Trust committed the Trust to fund the building and equipping of the CRC at St. James’s Hospital. At the end of June the HRB and TCD agreed a revised contract for the DCCR supporting the DCCR until December 2014. This revised contract provides for an independent Oversight Board that will monitor and report on the progress of the DCCR to TCD, Wellcome Trust and the HRB.
MMI agrees position paper calling for Ireland's continued participation in EU biobanking and clinical research infrastructures
MMI has agreed a position paper recommending that Ireland commits to full membership of the European Research Infrastructure Consortiums (ERICS) for two European biomedical research infrastructures: Biobanking and Biomolecular Resources Infrastructure (BBMRI) and the European Clinical Research Infrastructure Network (ECRIN). MMI and ICRIN are the Irish scientific partners of BBMRI and ECRIN respectively, and the ERIC is the legal instrument agreed by the European Council of Ministers in 2009 to provide a governance framework for the next phase of the development of the European research infrastructures.
To view the position paper please click here.
For information on ECRIN please go to: www.molecularmedicineireland.ie/page/g/t/25
For information on BBMRI please go to : www.molecularmedicineireland.ie/page/g/t/39
Date for the diary - Workshop on Sponsorship and Governance of Clinical Research
Molecular Medicine Ireland is organising a half day workshop to address the issue of sponsorship of clinical research and to identify solutions on Thursday 16 September in Dublin – venue to be announced.
The workshop will explore why an effective and coherent framework for research governance and sponsorship is the necessary foundation to guarantee that Irish research activities will be performed to best national and international research practice. It will examine how this framework assures funders and agencies that PIs performing research are doing so in an environment which assures the correct level of research oversight, research compliance and adherence to the appropriate legislative and regulatory requirements.
The workshop will sketch the current landscape of research governance and sponsorship nationally and internationally. Furthermore, it will identify what needs to be done to optimise and facilitate PIs to perform research in a supportive environment in all types of research involving human participants, such as, medicinal products, surgical and radiotherapy research, biomarker and diagnostic research, medical devices, stem cell and other advanced therapies and neutraceuticals.
The outputs will focus on issues and propose solutions to enable:
•Single centre research
•Multi-centre research in Ireland only
•Multi-centre and multi-national research – where an Irish Institution is acting as research lead/sponsor or as participant in externally sponsored project
The workshop will look at the current developments in addressing the needs of research governance and sponsorship using case studies which showcase the progress to date and the challenges remaining.
Speakers include Professor Stephen K. Smith, Principal of the Faculty of Medicine and Chief Executive of Imperial College Healthcare NHS Trust, Professor William Powderly, Chief Academic Officer, Dublin Academic Health Care and Head of School, UCD School of Medicine and a representative of the Irish Medicines Board.
The target audience are PIs, Clinical Scientists, Hospital and University based clinical researchers and research directors and managers, CEOs and Hospital managers, ethics committee representatives, sponsors of research in medicinal products, medical devices and diagnostics and agencies that interface with the variety or research activities being conducted by the Irish research community, research funders and economic development agencies.
To register an interest in attending this workshop please email : info@molecularmedicineireland.ie
ICRIN invites applications for the next GCP course on Friday 16th July 2010, which will take place in St Vincent's Hospital, Dublin 4
This introductory course will provide a good overview to those interested/working in clinical research. In addition it provides the mandatory training required for those working in investigational medicinal product trials
Fees: Academic rate - 100 Euros, Industry/non-academic rate - 400 Euros
The academic rate will be applicable to the following personnel:
- All hospital and university employees
- Employees of all hospital Clinical Research Centres (CRC)
- Molecular Medicine Ireland Employees
- Employees of charitable organisations
The non-academic rate will be applicable to the following personnel:
- Pharmaceutical Industry Employees
- Medical Device Industry Employees
- State and Semi-State Bodies
- Industry funded clinical staff
Registration
This course will take place in the Education & Reserarch Centre, St Vincent's Hospital on Friday 16th July from 09:30 to 16:00
Please e-mail siobhan.gaynor@molecularmedicineireland.ie if you wish to be registered , with your contact details and job title.
You will be then contacted closer to the date with further information
MMI/ICRIN contributes to ECRIN publications
The European Clinical Research Infrastructures Network (ECRIN) has started to publish on the issue of lack of harmonisation when conducting clinical research in Europe. Contributing to two of their publications are ICRIN Senior Associate, Siobhan Gaynor and ICRIN's former Co-ordinator, Margaret Cooney. Professor Tim O' Brien, a director of the MMI Board, also contributed to a publication.
ECRIN is a sustainable, not-for-profit infrastructure supporting multinational clinical research projects in Europe. It is based on the connection of coordinating centres for national networks of clinical research centres and clinical trials units who are able to provide support and services to multinational clinical research. In Ireland, MMI/ICRIN participates in ECRIN projects and Siobhan Gaynor (ICRIN) is the National European Correspondent for ECRIN.
MMI Course Visit to Trinity College Dublin's 3D Visualisation Facility
Attendees of the fourth running of the MMI Drug Design & Delivery course, which took place on 12-13 October 2009 in RCSI, visited the TCD 3D visualisation facility on Wednesday 10 February 2009.
The visit was led by Dr Amir Khan (School of Biochemistry and Immunology, TCD) and included a demonstration of Estrogen Receptor bound to antagonists. This visit gave participants an excellent opportunity to see at first hand some state-of-the-art technology that enables researchers to view the interactions between receptors and candidate drugs.
The development of this expertise is of great importance as new scientific visualisation techniques and tools help increase the understanding of complex scientific data. These three dimensional visualisation techniques also allow scientists to display their results in a more understandable way, allowing non-scientific spectators to grasp the meaning of the scientific research. This can help make the knowledge generated by the researchers more accessible.
Should you wish to read a report on the MMI Drug Design & Delivery course, please click here
Find also further information on the Institute for Information Technology and Advanced Computation (IITAC) Visualisation Facilitiesat TCD via the following link:
http://www.iitac.tchpc.tcd.ie/facilities/vis/
Predictive Biomarkers in Breast Cancer Discovered by Research Team including MMI Clinician Scientist Fellow
A team led by Dr Leonie Young of RCSI, including MMI Clinician Scientist Fellow Dr Damian McCartan and researchers based in UCD, has published important research with applications in the diagnosis and treatment of breast cancer. About 70% of breast cancers are oestrogen receptor positive – the cancer cells contain oestrogen hormone receptors and the hormone stimulates the cancer cells to multiply. Standard therapy incorporates treatments to reduce the level of oestrogen or block its action on cells. However, in some cases (25-30%) the cancer re-grows. The team have discovered two predictive biomarkers, one in tissue and the other in blood serum, that can give advance warning if a patient is likely to have a poor response to standard therapies. This enables the clinician to select an alternative more aggressive therapy at an earlier stage. The College recently launched the research findings and is hoping to develop a test with a commercial partner.
The research was supported by Science Foundation Ireland and Breast Cancer Ireland.
Dr Damian McCartan holds an MMI Clinician Scientist Fellowship. The MMI Clinician Scientist Fellowship Programme is funded through PRTLI Cycle 4 administered by the Higher Education Authority.
Links
Irish Times article: http://www.irishtimes.com/newspaper/ireland/2010/0525/1224271087415.html
Research publication:
McIlroy M, McCartan D, Early S, Gaora PO, Pennington S, Hill AD, Young LS. (2010). Interaction of Developmental Transcription Factor HOXc11 with Steroid Receptor Coactivator SRC-1 Mediates Resistance to Endocrine Therapy in Breast Cancer. Cancer Res. 70, 1585-1594. http://cancerres.aacrjournals.org/cgi/content/abstract/70/4/1585
MMI Clinician Scientist Fellowship Programme: http://www.molecularmedicineireland.ie/csfp
Funding confirmed for Galway Clinical Research Facility
Professor Larry Egan pointing at the architectural design of the new Clinical Research Facility Galway with Mary Harney TD
On 12th February, Professor Larry Egan, Interim Director of the Health Research Board Clinical Research Facility Galway, welcomed the announcement by the Minister for Health & Children, Mary Harney TD, that € 7.5m in capital funding is being provided for a new Clinical Research Facility to be constructed on the grounds of University Hospital Galway. This HRB-funded clinical research facility is a joint venture between Galway University Hospital and NUI Galway and has been operating since March of 2008.
Professor Egan commented, “The benefits of this facility include the ability to provide access to cutting-edge clinical trials and access to novel therapies for patients in the West of Ireland. Clinical care provided in a research-intensive environment has been proven internationally to result in the best patient outcomes. With the development of the Clinical Research Facility in Galway, our ability to provide this level of service to our patients will be significantly enhanced. As a result, patient care will improve, and the ability of our hospital to attract and retain the very best medical and allied health staff would be improved. Moreover, the capabilities for investigation at this facility will provide an important and highly valuable opportunity for Irish companies operating in the biomedical research area such as pharmaceuticals and biomedical device companies to add value to their products through high quality clinical research”.
The above piece has been editted from a news item on the NUI Galway website entitled " € 7.5million funding for new Clinical Research Facility". For the full text click on link below.
http://www.nuigalway.ie/about-us/news-and-events/news.php?p_id=1224
News in Brief
Science Bus travels to Turin to promote Dublin as European City of Science in 2012
A group of six young Irish science enthusiasts left Dublin on 20 June to travel to Turin, the European City of Science in 2010, to take part in the city's science celebrations between 2 - 7 July. They are travelling on a specially commissioned Science Communications Bus and will stop off at scientific landmarks in cities such as… More »
Irish scientists uncover genetic secrets of human adaptation to high altitude
A group of top international scientists including geneticists from the Royal College of Surgeons in Ireland (RCSI) has made a breakthrough in understanding human adaptation to high altitude environments.
The new study identifies a gene in Tibetan highlanders, who live high in the Himalayas, which allows them to thrive at altitudes more… More »
TCD & UCD Researchers Discover New Autism Genes as Part of Major International Research Project
New autism genes have been discovered by researchers at Trinity College Dublin and University College Dublin as part of a Global Autism Genome Project, involving 50 institutions worldwide.
The Irish component of the work of the Autism Genome Project involves a collaboration between TCD and UCD and focused on the identification… More »
CRANN opens state of the art Advanced Microscopy Laboratory in Dublin
CRANN’s Advanced Microscopy Laboratory (AML) was opened on April 2th by Minister for Labour Affairs, and Public Service Transformation, Mr Dara Calleary, TD. The AML is a world class nanoscience research, which features some of the world’s most advanced microscopes allowing material to be viewed at the atomic scale. It will allow Ireland to compete… More »
Upcoming Events
- BIOPHOTONICS & IMAGING GRADUATE SUMMER SCHOOL
8 Jun 2010 to 3 Sep 2010 - BioPIC Conference 2010: 18th-20th October
18 Oct 2010 to 20 Oct 2010 - Summer School in Biostatistics 2010 - HRB Clinical Research Facility, Galway
28 Jun 2010 to 2 Jul 2010 - Dublin Academic Medical Centre Summer School 2010
7 Jul 2010 to 9 Jul 2010